- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 31/18 - Antivirals for RNA viruses for HIV
Patent holdings for IPC class A61P 31/18
Total number of patents in this class: 4256
10-year publication summary
|
116
|
220
|
256
|
264
|
265
|
238
|
229
|
202
|
181
|
35
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Gilead Sciences, Inc. | 2157 |
270 |
| Duke University | 3167 |
86 |
| ViiV Healthcare UK (no.5) Limited | 89 |
76 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2958 |
65 |
| ViiV Healthcare Company | 164 |
63 |
| Mondobiotech Laboratories AG | 311 |
56 |
| Bristol-myers Squibb Company | 4793 |
52 |
| Merck Sharp & Dohme LLC | 3719 |
51 |
| Centre National de La Recherche Scientifique | 10830 |
46 |
| Merck Sharp & Dohme Corp. | 2186 |
41 |
| The Scripps Research Institute | 1342 |
41 |
| The Trustees of the University of Pennsylvania | 4396 |
35 |
| The Regents of the University of California | 20447 |
34 |
| Emory University | 1691 |
32 |
| Shionogi & Co., Ltd. | 833 |
31 |
| Janssen Sciences Ireland Unlimited Company | 386 |
31 |
| The Rockefeller University | 585 |
27 |
| Cipla Limited | 470 |
24 |
| Janssen Vaccines & Prevention B.V. | 294 |
24 |
| F. Hoffmann-La Roche AG | 7882 |
23 |
| Other owners | 3148 |